培马贝特治疗非酒精性脂肪性肝病的随机对照试验
这项2期双盲安慰剂对照试验纳入118例高危NAFLD患者,随机接受培马贝特0.2mg或安慰剂每日两次口服72周。主要终点第24周MRI-PDFF变化两组无显著差异,但培马贝特组第48周和第72周MRE肝硬度显著下降,ALT和LDL-C也显著降低,耐受性良好。
要点
- 培马贝特未显著降低NAFLD患者肝脏脂肪含量
- 培马贝特显著降低MRE肝硬度并维持至72周
- 培马贝特可能作为NAFLD/NASH治疗或联合治疗候选
核心结论
- 培马贝特未降低肝脏脂肪含量,但显著降低MRE肝硬度,可能是有前景的NAFLD/NASH治疗药物及联合治疗候选。
研究设计与样本
- 双盲、安慰剂对照、随机多中心2期试验,纳入118例高危NAFLD患者,1:1随机接受培马贝特0.2mg或安慰剂口服每日两次,持续72周。
主要发现
- 主要终点第24周MRI-PDFF百分比变化两组无显著差异(-5.3% vs -4.2%;治疗差异-1.0%,P=0.85)。
- 第48周MRE肝硬度较安慰剂显著下降(治疗差异-5.7%,P=0.036),第72周维持(治疗差异-6.2%,P=0.024)。
- 培马贝特组ALT和LDL-C显著降低,不良事件与安慰剂组相当,耐受性良好。
关键数值与推荐
- 关键入选标准包括MRI-PDFF肝脂肪含量≥10%、MRE肝硬度≥2.5 kPa及ALT升高。
- 主要终点为基线至第24周MRI-PDFF百分比变化。
- 次要终点包括MRE肝硬度、ALT、血清肝纤维化标志物和血脂参数。
临床怎么用
- 培马贝特可考虑用于降低NAFLD患者肝硬度,尤其适合与减脂药物联合治疗。
- 治疗期间需监测肝硬度、ALT和血脂变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pemafibrate is a novel, selective peroxisome proliferator-activated receptor α modulator (SPPARMα). In mice, Pemafibrate improved the histological features of non-alcoholic steatohepatitis (NASH). In patients with dyslipidaemia, it improved serum alanine aminotransferase (ALT). AIMS: To evaluate the efficacy and safety of Pemafibrate in patients with high-risk, non-alcoholic fatty liver disease (NAFLD). METHODS: This double-blind, placebo-controlled, randomised multicentre, phase 2 trial randomised 118 patients (1:1) to either 0.2 mg Pemafibrate or placebo, orally, twice daily for 72 weeks. The key inclusion criteria included liver fat content of ≥10% by magnetic resonance imaging-estimated proton density fat fraction (MRI-PDFF); liver stiffness of ≥2.5 kPa, by magnetic resonance elastography (MRE); and elevated ALT levels. The primary endpoint was the percentage change in MRI-PDFF from baseline to week 24. The secondary endpoints included MRE-based liver stiffness, ALT, serum liver fibrosis markers and lipid parameters. RESULTS: There was no significant difference between the groups in the primary endpoint (-5.3% vs -4.2%; treatment difference -1.0%, P = 0.85). However, MRE-based liver stiffness significantly decreased compared to placebo at week 48 (treatment difference -5.7%, P = 0.036), and was maintained at week 72 (treatment difference -6.2%, P = 0.024), with significant reduction in ALT and LDL-C. Adverse events were comparable between the treatment groups and therapy was well tolerated. CONCLUSIONS: Pemafibrate did not decrease liver fat content but had significant reduction in MRE-based liver stiffness. Pemafibrate may be a promising therapeutic agent for NAFLD/NASH, and also be a candidate for combination therapy with agents that reduce liver fat content. ClinicalTrials.gov, number: NCT03350165.
引用
- Nakajima A, Eguchi Y, Yoneda M, et al. Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2021. PMID: 34528723. doi:10.1111/apt.16596
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。